Falber_Stuart

Stuart M. Falber

Falber_Stuart

Stuart M. Falber

Partner

  • Co-Chair, Life Sciences Group
Boston + 1 617 526 6663

Stuart Falber exclusively represents clients in the life sciences area. For more than 30 years, Mr. Falber has served as counsel for a broad range of life sciences clients, ranging from startup private companies to mature public companies, investment banks, venture capital funds and scientific funds.

Mr. Falber's practice focuses on corporate and securities law, with an emphasis on private and public company counseling; representation of issuers, investment banks and investors in venture capital transactions, public offerings and other financing transactions; mergers and acquisitions, including public and private company acquisitions and dispositions, asset acquisitions and sales, and public and private company spinoffs; and corporate collaborations and licensing transactions.

Learn more about Mr. Falber's practice and how he can support your startup on WilmerHaleLaunch.com.

Professional Activities

Mr. Falber is a member of the American Bar Association, the Massachusetts Bar Association and the Boston Bar Association. He previously served as a member of the Boston Bar Association's 2017 Life Sciences Conference Advisory Committee.

Experience

  • Venture Capital Transactions

    • Seaport Therapeutics in its $100 million Series A financing round and $225 million Series B financing round
    • Ascidian Therapeutics, Inc. in its $50 million Series A financing round
    • Flare Therapeutics, in its $123 million Series B financing round
    • Intergalactic Therapeutics, Inc. in its $75 million Series A financing round
    • Nexo Therapeutics in its $60 million Series A financing round
    • Rectify Pharmaceuticals in its $96 million Series A financing round
    • Ratio Therapeutics, Inc. in its $50 million Series B financing round
    • Sonde Health in its $19.25 million Series B financing round
    • Third Harmonic Bio, Inc. in its $50 million Series A financing round
    • Atlas Venture, Abingworth Ventures, Forbion Capital Partners and other funds in venture and strategic financings

  • Public Offerings

    • Aileron Therapeutics, Inc., in its initial public offering and in multiple follow-on offerings including a $35.9 million public offering and a $20 million public offering
    • Apellis Pharmaceuticals, Inc. in its $150 million initial public offering and in multiple follow-on offerings, including $402 million public offerings
    • Decibel Therapeutics, Inc. in its $137 million initial public offering
    • Dyne Therapeutics in its $268 million initial public offering and in multiple follow-on  public offerings raising a total of $620 million
    • Epizyme in multiple follow-on public offerings, including a $172.5 million public offering and an $85 million public offering
    • Generation Bio Co. in its $230 million initial public offering and $225 million follow-on public offering 
    • Ocular Therapeutix, Inc. in its $115 million follow-on public offering
    • Tetraphase Pharmaceuticals, Inc. in its $80.5 million initial public offering and in multiple follow-on public offerings, including its registered direct offerings
    • Tokai Pharmaceuticals in its $105.3 million initial public offering
    • Trevi Therapeutics, Inc. in its initial public offering and multiple follow-on public offerings including a $58 million public offering
    • The underwriters in the IPO and follow-on public offering of Amylyx Pharmaceuticals, Inc. 
    • Numerous ATM offerings for clients

  • Merger and Acquisition Transactions

    • Aileron Therapeutics in its reverse merger transaction with Lung Therapeutics
    • Alkermes in its acquisition of Rodin Therapeutics for an upfront cash payment of $100 million and up to $850 million in potential milestone payments
    • Braintree Laboratories in its sale to Sebela Pharmaceuticals
    • Decibel Therapeutics, Inc. in its sale to Regeneron Pharmaceuticals, Inc. 
    • Disarm Therapeutics in its sale to Eli Lilly and Company for an upfront payment of $135 million
    • Epizyme in its sale to Ipsen for $247 million
    • Gemini Therapeutics, Inc.in its $175 million reverse merger transaction with Disc Medicine
    • Gloucester Pharmaceuticals, Inc. in its sale to Celgene, Inc. for up to $640 million, including contingent payments
    • Investors Abingworth Bioventures and Atlas Venture in the sale of IFM Therapeutics to Bristol-Myers Squibb
    • Millendo Therapeutics in its reverse merger with Tempest Therapeutics
    • Penwest Pharmaceuticals Co. in its sale to Endo Pharmaceuticals, Inc. for $144 million
    • Seaport Therapeutics in its spin-off from PureTech Health
    • Tetraphase Pharmaceuticals in its sale to La Jolla Pharmaceuticals
    • Tokai Pharmaceuticals Inc. in its reverse merger transaction with Otic Pharma Ltd.
    • Transkaryotic Therapies, Inc. in its sale to Shire Pharmaceuticals Group plc for $16 billion

  • PIPE and 144A Transactions

    • Aileron Therapeutics in multiple PIPE transactions
    • Apellis Pharmaceuticals in its $220 million and $329 million convertible note offerings and in its $107.5 million convertible note exchange  
    • Apellis Pharmaceuticals in its $126 million PIPE transaction
    • Argos Therapeutics, Inc. in multiple PIPE transactions, including its $60 million PIPE transaction
    • Kala Bio in multiple PIPE transactions
    • Ocular Therapeutix, Inc. in its $325 million PIPE transaction
    • The Medicines Company in 144A convertible note offerings, including its $400 million offering
    • Trevi Therapeutics, Inc. in its $55 million PIPE transaction

  • Corporate Collaborations and Licensing Transactions

    • Apellis Pharmaceuticals, Inc. in a risk-sharing collaboration with SFJ Pharmaceuticals
    • Epizyme in a collaboration with Royalty Pharma, including equity and royalty sale
    • ZIOPHARM Oncology, Inc., Braintree Laboratories, Inc. and Idera Pharmaceuticals, Inc. in various licensing transactions

Recognition

  • Award Text

    Selected as a “Go To Lawyer” in Massachusetts

    Massachusetts Lawyers Weekly

    2021

  • Award Text

    Named Among the Best Lawyers in America for Biotechnology, Life Sciences and Corporate Law

    Best Lawyers in America

    2017–2023

  • Award Text

    Shortlisted for Corporate Attorney of the Year

    LMG Life Sciences

    2023

  • Recognized by LMG Life Sciences as a "Life Sciences Star" in 2018–2023 and shortlisted as the 2019 and 2023 Corporate Attorney of the Year.
  • Named one of the 2017–2023 Best Lawyers in America in the areas of biotechnology, life sciences and corporate law.
  • Named a 2021 "Go To Lawyer" by Massachusetts Lawyers Weekly in its inaugural ranking of business lawyers.
  • Named to Boston Magazine’s inaugural Top Lawyers list in 2021, 2022 and 2023 in the area of corporate law.
  • Recommended by The Legal 500 United States for healthcare: life sciences and capital markets: equity offerings.

Insights & News

View all of Stuart's insights & news

Credentials

  • Education

    • JD, University of Pennsylvania Law School

      magna cum laude Order of the Coif; Senior Editor, University of Pennsylvania Law Review

    • BA, Tufts University

      cum laude

  • Admissions

    • Massachusetts

Credentials

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel